3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Breast Neoplasms
40
HER2-positive Breast Cancer
6
Neoplasm Metastasis
2
Inflammatory Breast Neoplasms
2
Colonic Neoplasms
2
Stomach Neoplasms
1
Solid Tumors
1
Resectable HER2-positive Breast Cancer
1
Patient Preference
1
Pathologic Complete Response
1
Ovarian Neoplasms
1
Neoplasms
1
Invasive Breast Cancer
1
HR Negative HER2 Positive Early Breast Cancer or Locally Advanced Breast Cancer Patients
1
HER2-positive Metastatic Breast Cancer
1
HER2-positive Early Breast Cancer
1
HER2+ Breast Cancer
1
HER2 Positive Early Breast Cancer
1
Esophageal Neoplasms
1
Endometrial Neoplasms
1
Early-stage or Locally Advanced HER2-positive Breast Cancer
1
Early or Locally Advanced HER2-positive Breast Cancer
1
Carcinoma, Ductal, Breast
1
Breast Diseases
1
Anatomic Stage IV Breast Cancer AJCC v8
1
Anatomic Stage I Breast Cancer AJCC v8
1
Advanced HER2+Breast Cancer
1
Adenocarcinoma Of Esophagus
1
Interventions
pertuzumab
1
Trastuzumab
1
Alpelisib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Advanced HER2+Breast Cancer
×
pertuzumab
×
Clear all
NCT04208178
2026-04-02
EPIK-B2
Novartis
Phase 3
Active not recruiting
19 enrolled